Overview of Fibator-LS

Quick Facts

Property	Description
Active ingredients	Atorvastatin, Fenofibrate
Form	Tablet
Pharmacological class	Dyslipidaemic Agent (Statin + Fibrate)
Common use	Management of mixed dyslipidaemia
Origin	Synthetic chemical compounds

What Type of Medicine is Fibator-LS? (Identity and Classification)

Fibator-LS is a prescription-only fixed-dose combination (FDC) product, classified as a comprehensive Dyslipidaemic Agent or lipid-lowering agent. It is an oral medication presented in tablet form. This formulation represents a specialized therapeutic approach, combining two distinct synthetic compounds into a single pill to address multiple blood fat abnormalities. The clinical rationale for using an FDC like Fibator-LS is utilized for potentially improving patient adherence to dual therapy compared to taking two separate tablets. The entity is fundamentally defined by its ability to modulate both cholesterol and triglyceride pathways simultaneously for effective lipid management.

What Active Ingredients Does Fibator-LS Contain? (Composition and Class)

The medicine contains two active ingredients: Atorvastatin and Fenofibrate. These ingredients belong to separate, complementary pharmacological classes. Atorvastatin is a Statin, formally an HMG-CoA Reductase Inhibitor, which primarily reduces the liver's production of LDL cholesterol. Fenofibrate is a Fibrate, which functions as a PPARα agonist, enhancing the breakdown of fatty particles in the bloodstream. This composition positions Fibator-LS as a singular pill designed to deliver the benefits of both a potent cholesterol reducer and a primary triglyceride adjuster, often a necessity in patients with complex lipid disorders.

What is the General Purpose of Fibator-LS? (Benefit and Goal)

The general purpose of Fibator-LS is the intensive management of mixed dyslipidaemia, a condition where patients have abnormally high levels of both LDL cholesterol and Triglycerides (TG). It is intended as an adjunct to diet and lifestyle modifications. A typical use scenario involves managing an adult patient whose lipid profile requires simultaneous, significant reduction of both cholesterol and triglycerides. The medicine aims to restore a healthier balance of fats in the blood, thereby addressing the underlying abnormalities associated with heightened cardiovascular risk.

What side effects are possible with Fibator-LS?

Possible Side Effects and Safety Information

The safety profile for Fibator-LS, a fixed-dose combination containing Atorvastatin and Fenofibrate, is derived from the adverse reactions officially documented for its individual components. Regulatory documents categorize these reactions primarily by frequency and the body system affected, providing a structured understanding of the medicine’s risk profile.

Frequency-Classified Adverse Reactions

The most commonly reported adverse effects in regulatory labeling are classified as Common (may affect up to 1 in 10 people). These frequently involve the Musculoskeletal and Connective Tissue Disorders, presenting as muscle pain (myalgia), joint pain (arthralgia), and pain in the extremities. Gastrointestinal issues such as diarrhea, abdominal pain, nausea, and flatulence are also commonly listed. Increases in liver enzyme levels (transaminases) have also been documented as a common finding.

Serious Adverse Reactions and Safety Constraints

Official labeling specifically highlights the potential for rare but serious adverse reactions. The most significant of these include Rhabdomyolysis (severe breakdown of muscle tissue), Hepatitis/Hepatic Failure, and Pancreatitis.

The medicine is subject to strict regulatory constraints. It is generally contraindicated in patients with pre-existing conditions, including Active Liver Disease, Severe Renal Dysfunction, and known Gallbladder Disease. For certain populations, such as the elderly, caution is advised due to the potential for increased susceptibility to muscle-related adverse events. While muscle effects can appear at any time, regulatory safety notes often document reports occurring more frequently in the first few months of treatment.

Overdose and Emergency Response

The official regulatory documentation on Fibator-LS overdose, which combines Atorvastatin and Fenofibrate, indicates that clinical experience with acute overdose is limited. Consequently, the prescribing information does not define a specific, unique symptom profile or set of clinical manifestations resulting solely from excessive intake of the active components.

In the event of a suspected overdose, immediate medical attention must be sought. Emergency medical services should be contacted immediately if the affected individual experiences severe signs such as collapse, seizure, difficulty breathing, or a state where they cannot be awakened. This action is a standard, non-negotiable step mandated by regulatory guidance.

There is no specific antidote known or available to counteract the effects of Fibator-LS overdose. Therefore, the official management strategy is focused entirely on symptomatic and supportive treatment to manage any resulting clinical effects. As general supportive measures, healthcare professionals may consider procedures like gastric lavage or the administration of activated charcoal to limit further systemic absorption of the drug. Furthermore, official documentation notes that hemodialysis is not expected to be useful for accelerating drug removal due to the extensive plasma protein binding of both Atorvastatin and Fenofibrate. Continuous clinical monitoring of the patient's status is required throughout the management period.

Therapeutic Uses of Fibator-LS

Fibator-LS is a combination therapy indicated for supporting the management of mixed dyslipidemia, a condition characterized by high cholesterol and elevated triglyceride levels. The medicine is primarily used to address two main scenarios: elevated cholesterol (specifically high low-density lipoprotein cholesterol, or LDL-C) and high triglyceride levels (hypertriglyceridemia). By helping to modulate these parameters, Fibator-LS may contribute to the overall management of cardiovascular risk. It supports the lowering of harmful cholesterol types while promoting an increase in beneficial high-density lipoprotein cholesterol (HDL-C) levels.

The therapy is also considered for patients diagnosed with coronary artery disease (CAD) who have a history of adverse cardiovascular events, such as a heart attack. In this clinical scenario, it may help stabilize the lipid profile as part of a secondary prevention strategy, used alongside appropriate lifestyle measures.

Quick Fact: Relief for Elevated Lipids Fibator-LS may support the reduction of fats in the blood, an effect considered crucial for long-term heart health.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fibator-LS — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults with mixed dyslipidaemia who do not have any contraindications documented in the medicine's labeling.
Populations for whom use is not recommended	Pediatric Population (children and adolescents under 18 years) due to safety and efficacy not being established.
Populations for whom use is contraindicated	Patients with Active Liver Disease; Patients with Severe Renal Impairment (eGFR <30 mL/min/1.73 m^2); Patients with Pre-existing Gallbladder Disease; Women who are pregnant or breastfeeding.

Eligibility Classifications (High-Level)

Category	Classification Details (as defined in official documents)
Eligibility severity classification	Absolute Contraindication (e.g., Active Liver Disease, Pregnancy); Not Recommended (e.g., Pediatric Use); Conditional Restriction (e.g., Moderate Renal Impairment).
Eligibility-context constraints	Constraints are tied primarily to organ function integrity (hepatic/renal) and reproductive status.

Resulting Eligibility Structure

Official Eligibility Statements:

The medicine is contraindicated in patients with active liver disease and in those with severe renal impairment.
Use is contraindicated during pregnancy and lactation.
The combination product is not recommended for use in the pediatric population.
Patients with pre-existing gallbladder disease are formally contraindicated from using the medicine.
Use is restricted or requires special consideration in patients with moderate renal impairment or those with uncontrolled hypothyroidism.

Connection to the overall eligibility profile: Regulatory documents define the permitted population as adults who are free from specific, pre-existing comorbidities that compromise hepatic or renal function and who are not pregnant or breastfeeding. These documented exclusions represent the most serious prohibitions associated with the drug's components, establishing clear boundaries for its official use.

What should I know about interactions with other medicines?

Documented Drug-Drug and Substance Interactions

Fibator-LS, a fixed-dose combination of Atorvastatin and Fenofibrate, has a regulatory profile structured around exposure modification and heightened risk. Co-administration with other Fibric Acid Derivatives, notably Gemfibrozil, is generally prohibited or strongly discouraged due to a significantly increased risk of severe muscle toxicity (rhabdomyolysis). Similarly, co-administration with systemic Fusidic acid is subject to regulatory avoidance for the same risk.

The plasma concentration of the Atorvastatin component is sensitive to metabolic inhibition. Strong inhibitors of the CYP3A4 enzyme (such as Clarithromycin or certain antivirals) and transporter inhibitors (such as Ciclosporin) are documented to increase Atorvastatin exposure.

A key pharmacodynamic interaction involves oral anticoagulants, like Warfarin. The Fenofibrate component enhances the anticoagulant effect, necessitating close monitoring of clotting parameters as specified in official guidelines. For certain co-administered substances, timing separation is mandatory; the Fenofibrate component must be administered at least one hour before or four to six hours after bile-acid binding resins to ensure proper absorption. Additionally, excessive consumption of Grapefruit juice is documented to increase Atorvastatin exposure, and cautions exist regarding excessive alcohol use and the avoidance of Red Yeast Rice supplements due to additive risk.

Mechanism of Action

Modulating Cholesterol Production via HMG-CoA Reductase Inhibition

The Atorvastatin component acts as a selective, competitive inhibitor of the enzyme HMG-CoA Reductase in the liver, which controls the rate-limiting step of endogenous cholesterol synthesis. This molecular blockade reduces the liver’s internal cholesterol supply, which triggers a compensatory cascade: the upregulation of LDL Receptors on liver cell surfaces. This leads to the receptor-mediated clearance of cholesterol-rich particles from the circulating blood.

Enhancing Triglyceride Breakdown via PPARalpha Agonism

The Fenofibrate component, through its active metabolite, functions as an agonist of the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha) nuclear receptor. Activation of PPARalpha initiates a transcriptional sequence that increases the synthesis of fat-clearing enzymes, such as Lipoprotein Lipase (LPL), and simultaneously decreases the synthesis of inhibitory proteins like Apolipoprotein C-III. This combined effect leads to the enhanced catabolism and systemic clearance of triglyceride-rich VLDL and chylomicron particles.

Complementary Mechanism Targeting and Physiological Adjustment

These two mechanisms are complementary, addressing the core lipid metabolism deficits through distinct pathways: one acts on cholesterol production while the other acts on triglyceride catabolism. This dual approach provides a broad physiological modulation, which influences the simultaneous reduction of circulating LDL-Cholesterol and Triglycerides.

Dosage and Administration Information

Fibator-LS is administered via the oral route as a single tablet, representing a fixed-dose combination of Atorvastatin and Fenofibrate. The standardized adult regimen is one fixed-dose tablet once daily. This schedule defines the medicine's role as a component of long-term lipid management, serving strictly as an adjunct to an appropriate diet and lifestyle modification program.

The administration of the tablet must be done by swallowing it whole; it is advised to avoid crushing, breaking, dissolving, or chewing the fixed-dose tablet. While timing may vary based on the specific formulation, the established frequency remains a single daily dose, and may be taken without regard to meals. If a dose is missed, the standard practice is to skip the missed dose and resume the normal routine with the next scheduled administration.

Usage principles include specific considerations for patient populations. Due to the Fenofibrate component, the fixed-dose tablet is not generally recommended for use in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m^2). Furthermore, patients with mild to moderate renal function decline require careful dose adjustment, which may render the fixed-dose combination unsuitable for that group. The product is not typically recommended for pediatric patients. Efficacy of the regimen is typically assessed by monitoring lipid levels periodically, with evaluation recommended as early as 4 to 8 weeks after initiation.

Recent Clinical Evidence

Evidence for Managing Mixed Dyslipidaemia

Research examined outcomes related to blood fat levels in adults with mixed dyslipidaemia, primarily using short-term Randomized Controlled Trials (RCTs). These trials measured changes in key lipid parameters, such as LDL Cholesterol and Triglycerides. The research reported measured changes in these parameters across the study groups. This evidence relies largely on these short-term biomarker measurements, which are considered surrogate outcomes.

Evidence Related to Cardiovascular Risk and Clinical Events

Evidence examined the effect of the combination approach on serious clinical events, such as heart attack or stroke. Large-scale, long-term RCTs were explored in high-risk populations. The long-term trials data show patterns related to the observation that the overall population studied was not associated with a statistically significant difference in these serious endpoints.

Non-Lipid Effects and Other Outcomes Studied

Smaller studies research examined effects beyond lipid modulation, including changes in Vascular Function and certain Inflammatory Biomarkers. Research describes patterns related to microvascular complications in cohorts with Type 2 Diabetes, but sample sizes were modest in the vascular studies.

Study Duration and Long-Term Follow-up

The comparative efficacy trials for lipid modification generally had limited follow-up durations. The long-term effects are not fully established for this specific fixed-dose combination itself, as extended data primarily comes from trials on the individual components.

Evidence in Defined Subgroups and Populations

The main clinical trials were evaluated in adult populations, including significant subgroups with Type 2 Diabetes Mellitus and established cardiovascular disease. Data for certain groups remain insufficient, particularly for groups like children or pregnant individuals.

What is Still Uncertain About the Research for Fibator-LS

A key limitation is the reliance on surrogate outcomes rather than long-term clinical endpoints to describe the research on the FDC. The certainty remains low regarding the long-term clinical endpoints for the populations examined, and comparative evidence is lacking against many other dual-therapy regimens.

Frequently Asked Questions (FAQ)

Common questions about Fibator-LS (FAQ)

Q: How quickly can someone expect Fibator-LS to start working?

Official guidelines recommend that efficacy, measured by changes in blood lipid levels, is initially evaluated as early as 4 to 8 weeks after starting treatment. This assessment period allows healthcare professionals to assess the initial impact on lipid levels.

Q: Are there any specific foods or drinks that should be avoided when using Fibator-LS?

Regulatory information includes a documented interaction with Grapefruit juice, and cautions exist against excessive alcohol consumption. The medicine is intended to be used strictly as an adjunct to an appropriate, low-fat diet.

Q: Can older adults safely use Fibator-LS?

Regulatory labeling advises caution when Fibator-LS is used in older adults. This is specifically noted because this population is a potential factor for increased susceptibility to muscle-related adverse events.

Q: What is the risk of muscle pain or weakness with Fibator-LS?

Official documents classify general muscle pain (myalgia) as a common adverse effect. They also highlight the potential for a serious, but rare, reaction involving the severe breakdown of muscle tissue, known as rhabdomyolysis.

Q: Does Fibator-LS interact with vitamin supplements or herbal remedies?

Official warnings specify that Fibator-LS should not be used with Red Yeast Rice supplements due to a potential for additive risk. Regulatory guidance recommends informing a healthcare professional about all supplements, including multivitamins, to screen for potential interactions.

Q: Is Fibator-LS the same type of medicine as Lipitor or Crestor?

Fibator-LS is a prescription-only product defined as a fixed-dose combination of two active ingredients: Atorvastatin (a Statin) and Fenofibrate (a Fibrate). Therefore, it is not a single-agent Statin like Lipitor or Crestor, but a dual-action medicine.

Q: How does Fibator-LS affect the numbers on a typical lipid panel?

Official documents describe that the combination is designed to reduce levels of LDL cholesterol and significantly lower Triglycerides. The Fenofibrate component is also associated with a measured increase in HDL cholesterol in research studies.

Q: Does Fibator-LS affect blood sugar levels for people with diabetes?

Changes in blood sugar are not listed as a common or serious adverse reaction in the regulatory labeling. However, clinical studies included significant numbers of patients with Type 2 Diabetes Mellitus in the examined population.

Q: What are the reported success rates of Fibator-LS in clinical trials?

Research evidence reported measured changes in blood lipid levels, specifically the reduction of LDL cholesterol and triglycerides, in short-term trials. Long-term studies on serious clinical events for the overall patient population did not show a statistically significant difference in these endpoints.

Q: Why might one doctor prescribe Fibator-LS while another prescribes a different medicine?

The rationale for using a fixed-dose combination like Fibator-LS is described in research as potentially improving patient adherence to dual therapy. Regulatory evidence indicates a lack of comparative data against many other dual-therapy regimens, and clinical choice is generally based on multiple factors, including adherence goals and specific patient needs.

Q: Can Fibator-LS affect thyroid function?

Official regulatory text includes a restriction for use in patients with uncontrolled hypothyroidism. This means that thyroid function is a specific health factor that must be considered by the prescriber when determining eligibility for the medicine.

Q: Do I need to take Fibator-LS at the exact same time every day?

The established frequency for this medicine is one fixed-dose tablet once daily. While regulatory information does not specify that the dose must be taken at the exact same minute, establishing a consistent daily routine is generally recommended for maximizing adherence to any medication.

Q: Do I need any special tests before I can start taking Fibator-LS?

Regulatory documents generally require monitoring of liver enzyme levels (transaminases) and lipid levels. These tests are typically required before starting and periodically during treatment with the medicine to monitor the body's response.

Q: Can I stop taking Fibator-LS if my condition seems better?

The medicine is defined as a component of long-term lipid management. Discontinuing the full course of treatment necessitates a medical reassessment of the underlying condition.

Q: Can people with high blood pressure take Fibator-LS?

High blood pressure (hypertension) is not listed in the official documents as a condition that prevents the use of Fibator-LS. Contraindications focus primarily on the integrity of hepatic, renal, and gallbladder function, as well as reproductive status.

Q: Is it true that Fibator-LS is sometimes prescribed for conditions other than high cholesterol?

Fibator-LS is officially indicated for the management of mixed dyslipidaemia as an adjunct to diet. Regulatory documents limit the stated purpose to this specific indication only.

Q: Has the FDA (or similar agency) issued any recent warnings about Fibator-LS?

Regulatory agencies continuously monitor the safety of approved medicines, including Fibator-LS, through mandatory reporting and post-marketing surveillance. This process ensures the official safety profile is tracked and updated as needed.

Q: Can a person become dependent on or addicted to Fibator-LS?

Fibator-LS is not classified as a controlled substance by regulatory agencies. Official labeling does not describe dependence or addiction related to the medicine.

Q: Is the medication more effective when taken in the morning or at night?

The established frequency is one fixed-dose tablet once daily, and the tablet may be taken without regard to meals. Official documents do not specify whether morning or night-time dosing affects effectiveness.

Q: Why do official sources list so many potential drug interactions for Fibator-LS?

The need for multiple interaction warnings is due to the dual nature of the medicine. The Atorvastatin component is metabolized by the CYP3A4 enzyme, and the Fenofibrate component acts as a PPARα agonist, both of which have the potential to interact with other medicines.

Q: Are there any restrictions on driving or operating machinery while on Fibator-LS?

Regulatory documents usually include a precaution or statement if adverse effects like dizziness or lightheadedness are common enough to affect the ability to drive or operate machinery. If such effects are noted, patients are generally cautioned against performing activities that require alertness.

Q: Is Fibator-LS gluten-free or suitable for people with food allergies?

Official labeling lists the inactive ingredients, also called excipients, contained in the tablet formulation. This information is available to healthcare professionals for checking common allergens such as gluten or lactose.

Q: Do different strengths of Fibator-LS have different side effects?

Clinical trials sometimes evaluate and report adverse reactions based on the dosage strength of the individual components. Side effects are typically related to the overall exposure to the active ingredients in the body.

Q: How long does Fibator-LS stay in your system after stopping it?

Pharmacokinetic data for the active ingredients, Atorvastatin and Fenofibric Acid, includes information on the time required for the substances to be cleared from the body, known as the half-life. This data is available in official product information.

Q: What if I'm already taking medicine for another heart condition—can I still use Fibator-LS?

The combination of active ingredients has documented drug-drug interactions, including with the blood thinner Warfarin. The use of other heart condition medicines necessitates a careful review for potential drug interactions.

How should Fibator-LS be stored and disposed of?

How to Store and Dispose of Fibator-LS?

The official storage and disposal requirements for this medication are defined in regulatory labeling to maintain product stability and safety. Fibator-LS must be stored at controlled room temperature, typically below 25 C or within the range of 20 C to 25 C.

Storage Requirements

Temperature: Store at room temperature, below 25 C.
Protection: Keep the medicine protected from moisture, heat, and direct sunlight.
Accessibility: It is strictly required to keep Fibator-LS out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Proper Discarding: When the medication is expired or no longer needed, it must be properly discarded.
Prohibition: Do not flush Fibator-LS down the toilet or pour it into a drain, as specified by official guidelines for safe medicine disposal.

Fibator-LS